Sanofi | CIK:0001121404 | 3

  • Filed: 3/16/2018
  • Entity registrant name: Sanofi (CIK: 0001121404)
  • Generator: Donnelley Financial Solutions
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/0001193125-18-084834-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1121404/000119312518084834/sny-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001121404
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory

    B.5. Property, plant and equipment

    Property, plant and equipment is initially measured and recognized at acquisition cost, including any directly attributable cost of preparing the asset for its intended use, or (in the case of assets acquired in a business combination) at fair value as of the date of the business combination. The component-based approach to accounting for property, plant and equipment is applied. Under this approach, each component of an item of property, plant and equipment with a cost which is significant in relation to the total cost of the item and which has a different useful life from the other components must be depreciated separately.

    After initial measurement, property, plant and equipment is carried at cost less accumulated depreciation and impairment, except for land which is carried at cost less impairment.

    Subsequent costs are not recognized as assets unless (i) it is probable that future economic benefits associated with those costs will flow to Sanofi and (ii) the costs can be measured reliably.

    Borrowing costs attributable to the financing of items of property, plant and equipment, and incurred during the construction period, are capitalized as part of the acquisition cost of the item.

    Government grants relating to property, plant and equipment are deducted from the acquisition cost of the asset to which they relate.

    In accordance with IAS 17 (Leases), items of property, plant and equipment leased by Sanofi as lessee under finance leases are recognized as an asset in the balance sheet, with the related lease obligation recognized as a liability. A lease qualifies as a finance lease if it transfers substantially all of the risks and rewards of ownership of the asset to Sanofi. Assets held under finance leases are carried at the lower of the fair value of the leased asset or the present value of the minimum lease payments, and are depreciated over the shorter of the useful life of the asset or the term of the lease.

    The depreciable amount of items of property, plant and equipment, net of any residual value, is depreciated on a straight line basis over the useful life of the asset. The useful life of an asset is usually equivalent to its economic life.

      

    The customary useful lives of property, plant and equipment are as follows:

     

    Buildings    15 to 40 years
    Fixtures    10 to 20 years
    Machinery and equipment    5 to 15 years
    Other    3 to 15 years

    Useful lives and residual values of property, plant and equipment are reviewed annually. The effect of any adjustment to useful lives or residual values is recognized prospectively as a change in accounting estimate.

    Depreciation of property, plant and equipment is recognized as an expense in the income statement, in the relevant classification of expense by function.